With the exclusion of variants in the WNT signaling pathway, variant TP53 carriers that developed cancer were significantly enriched for class 1–3 variants (Wilcoxon rank-sum test, P = 0.022) and class 4 (Wilcoxon rank-sum test, P = 0.022) variants in comparison with the cancer-free variant TP53 carriers (Supplementary Fig. S4). The gene discussed is TP53; the disease is cancer.